Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) is anticipated to post its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to announce earnings of ($0.1750) per share for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 7:00 AM ET.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($11.25) EPS for the quarter, missing the consensus estimate of ($1.03) by ($10.22).
Adial Pharmaceuticals Stock Down 3.4%
NASDAQ:ADIL opened at $4.88 on Tuesday. Adial Pharmaceuticals has a twelve month low of $1.31 and a twelve month high of $9.30. The business has a 50 day moving average price of $4.45 and a two-hundred day moving average price of $3.23. The company has a market cap of $12.80 million, a P/E ratio of -0.33 and a beta of 1.50.
Analyst Ratings Changes
Get Our Latest Stock Analysis on ADIL
About Adial Pharmaceuticals
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for addiction and related disorders, particularly alcohol use disorder. Its lead candidate, AD04, is a formulation of ondansetron being studied as a potential treatment for people with alcohol use disorder who have certain genetic markers. The company’s approach combines drug development with pharmacogenetic testing to identify patients who may be more likely to benefit from treatment. AD04 remains investigational and is not an approved therapy.
See Also
- Five stocks we like better than Adial Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
